BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova EN, Vovk EI, Starostin KM. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia. BMJ Open Gastroenterol 2020;7:e000368. [PMID: 32337059 DOI: 10.1136/bmjgast-2019-000368] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Narankiewicz D, Ruiz-Nava J, Buonaiuto V, Ruiz-Moreno MI, López-Carmona MD, Pérez-Belmonte LM, Gómez-Huelgas R, Bernal-López MR. Utility of Liver Function Tests and Fatty Liver Index to Categorize Metabolic Phenotypes in a Mediterranean Population. Int J Environ Res Public Health 2020;17:E3518. [PMID: 32443453 DOI: 10.3390/ijerph17103518] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Li Y, Yang Y, Li Y, Zhang P, Ge G, Jin J, Du T, Ma M, Na L, Ding L, Sheng H. Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis. J Int Med Res 2021;49:3000605211055378. [PMID: 34772312 DOI: 10.1177/03000605211055378] [Reference Citation Analysis]
3 Osipova D, Kokoreva K, Lazebnik L, Golovanova E, Pavlov C, Dukhanin A, Orlova S, Starostin K. Regression of Liver Steatosis Following Phosphatidylcholine Administration: A Review of Molecular and Metabolic Pathways Involved. Front Pharmacol 2022;13:797923. [DOI: 10.3389/fphar.2022.797923] [Reference Citation Analysis]
4 Ivashkin VT, Maevskaya MV, Shirokova EN, Maev IV, Samsonov AA, Sas EI, Palgova LK, Starostin K. Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational Studies. Drugs Real World Outcomes 2021;8:369-82. [PMID: 33993460 DOI: 10.1007/s40801-021-00250-x] [Reference Citation Analysis]
5 Park J, Choi J, Kim DD, Lee S, Lee B, Lee Y, Kim S, Kwon S, Noh M, Lee MO, Le QV, Oh YK. Bioactive Lipids and Their Derivatives in Biomedical Applications. Biomol Ther (Seoul) 2021;29:465-82. [PMID: 34462378 DOI: 10.4062/biomolther.2021.107] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Dajani AI, Abuhammour A. Agents for the treatment of fatty liver disease: focus on essential phospholipids. Drugs Ther Perspect 2021;37:249-64. [DOI: 10.1007/s40267-021-00838-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Zhang Y, Lv J, Zhang J, Lv Z, Yu M. Lipidomic-based investigation into the therapeutic effects of polyene phosphatidylcholine and Babao Dan on rats with non-alcoholic fatty liver disease. Biomed Chromatogr 2021;:e5271. [PMID: 34727379 DOI: 10.1002/bmc.5271] [Reference Citation Analysis]
8 Fan JG, Li Y, Yu Z, Luo XX, Zheng P, Hao X, Wang ZY, Gao F, Zhang GQ, Feng WY. Effectiveness and Economic Evaluation of Polyene Phosphatidyl Choline in Patients With Liver Diseases Based on Real-World Research. Front Pharmacol 2022;13:806787. [PMID: 35330831 DOI: 10.3389/fphar.2022.806787] [Reference Citation Analysis]